Anti-Mouse RANKL (CD254) – Biotin

Anti-Mouse RANKL (CD254) – Biotin

Product No.: R1355

[product_table name="All Top" skus="R1355"]

- -
- -
Clone
IK22/5
Target
RANKL
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD254, TRANCE, hRANKL2, sOdf, TNF-Related Activation-Induced Cytokine [TRANCE], Osteoprotegrin Ligan
Isotype
IgG2a κ
Applications
FC

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Immunogen
Purified Recombinant Mouse RANKL (>98%)
Product Concentration
0.5 mg/ml
Formulation
This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for RANKL antibody, clone IK22/5 for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100 μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Clone IK22/5 recognizes an epitope on mouse RANKL.
Background
RANKL antibody, clone IK22/5, recognizes receptor activator of NF-κB ligand (RANKL), also known as CD254, TNF-related activation-induced cytokine (TRANCE), tumor necrosis factor ligand superfamily member 11 (TNFSF11), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF). RANKL is a type II transmembrane protein belonging to the TNF cytokine superfamily and binds to the signaling receptor, RANK, or decoy receptor, osteoprotegerin (OPG). RANKL is expressed on osteoclasts and is essential for osteoclast differentiation, activation, and survival1. RANKL is also expressed on activated T cells and regulates T cell-dendritic cell (DC) interactions, enhancing DC activation and survival2-3. In addition, RANKL is crucial for lymph node, bone marrow, and thymus development4. Treatment with denosumab, an antibody directed against RANKL, is approved for the treatment of patients at high risk for bone fractures, including osteoporosis, and has shown anti-tumor effects5.
Antigen Distribution
RANKL is expressed on activated T cells and osteoclasts.

Antigen Details

Ligand/Receptor
RANK, OPG
PubMed
NCBI Gene Bank ID
Research Area
Cell Biology
.
Immunology

References & Citations

1. Park JH, et al. (2017) Mol Cells. 40(10):706-713
2. Wong BR, et al. (1997) J Biol Chem. 272(40):25190-4
3. Anderson, D. M., et al. (1997) Nature 390:175.
4. Ono T, et al. (2020) Inflamm Regen. 2020;40:2.
5. de Groot AF, at al. (2018) Cancer Treat Rev. 62:18-28
Flow Cytometry

Certificate of Analysis

- -
- -
No results found. Clear filters and try again?
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.